Illumina, Inc. $ILMN Shares Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 8.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 232,646 shares of the life sciences company’s stock after acquiring an additional 17,519 shares during the quarter. Russell Investments Group Ltd. owned 0.15% of Illumina worth $63,651,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Illumina in the 2nd quarter worth approximately $3,374,423,000. Primecap Management Co. CA acquired a new stake in shares of Illumina during the 2nd quarter worth approximately $617,981,000. Jupiter Topco LLC purchased a new position in shares of Illumina during the 2nd quarter valued at approximately $358,652,000. WCM Investment Management LLC increased its holdings in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Illumina in the 2nd quarter valued at $293,846,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of ILMN stock traded down $2.54 during trading hours on Friday, hitting $207.01. 1,229,158 shares of the company’s stock were exchanged, compared to its average volume of 2,291,458. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The firm has a market cap of $31.30 billion, a P/E ratio of 35.63, a P/E/G ratio of 2.84 and a beta of 1.46. The firm has a 50 day moving average of $249.02 and a two-hundred day moving average of $179.64. Illumina, Inc. has a fifty-two week low of $112.65 and a fifty-two week high of $309.35.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.34 EPS. Sell-side analysts forecast that Illumina, Inc. will post 5.43 EPS for the current year.

Insider Transactions at Illumina

In other news, Director Keith Meister sold 299,336 shares of Illumina stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $217.96, for a total value of $65,243,274.56. Following the sale, the director owned 1,409,851 shares in the company, valued at $307,291,123.96. This trade represents a 17.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 1,881,899 shares of company stock worth $415,905,954 over the last quarter. Company insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on ILMN shares. Weiss Ratings raised shares of Illumina from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday, November 2nd. Stephens lowered shares of Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price target on the stock. in a research report on Friday, October 23rd. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 1st. Canaccord Genuity Group upped their price objective on shares of Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, October 19th. Finally, Sanford C. Bernstein reissued a “market perform” rating and set a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $244.24.

Get Our Latest Analysis on ILMN

Key Illumina News

These are some of the ILMN news items that stood out recently:

  • Positive Sentiment: Illumina expanded its molecular residual disease research portfolio with a duplex-sequencing workflow and was selected to provide whole-genome sequencing for Singapore’s SG-INSIGHT study, supporting its clinical oncology and precision-medicine ambitions. Illumina Unveils Duplex Sequencing Workflow for MRD Research
  • Neutral Sentiment: Chief Accounting Officer Scott Ericksen sold 267 shares under a pre-arranged Rule 10b5-1 plan, a relatively small reduction in his holdings. SEC filing
  • Negative Sentiment: Director Keith Meister sold 280,091 shares for approximately $61.1 million across November 9–11, cutting his direct stake substantially. The scale of the sales could concern investors, although he retained a sizable holding. SEC filing

About Illumina

(Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Further Reading

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.